Stocks and Investing Stocks and Investing
Tue, August 22, 2023

Charles Duncan Reiterated (AXSM) at Buy and Held Target at $108 on, Aug 22nd, 2023


Published on 2024-10-28 06:03:22 - WOPRAI, Charles Duncan
  Print publication without navigation


Charles Duncan of Cantor Fitzgerald, Reiterated "Axsome Therapeutics, Inc." (AXSM) at Buy and Held Target at $108 on, Aug 22nd, 2023.

Charles has made no other calls on AXSM in the last 4 months.



There are 6 other peers that have a rating on AXSM. Out of the 6 peers that are also analyzing AXSM, 2 agree with Charles's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Jason Gerberry of "B of A Securities" Upgraded from Sell to Hold and Increased Target to $81 on, Tuesday, August 8th, 2023
  • Vikram Purohit of "Morgan Stanley" Maintained at Hold with Increased Target to $90 on, Monday, June 12th, 2023


These are the ratings of the 4 analyists that currently disagree with Charles


  • Graig Suvannavejh of "Mizuho" Maintained at Strong Buy with Increased Target to $100 on, Friday, August 11th, 2023
  • Raghuram Selvaraju of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $180 on, Tuesday, August 8th, 2023
  • David Amsellem of "Piper Sandler" Upgraded from Hold to Buy and Increased Target to $90 on, Tuesday, August 8th, 2023
  • Yatin Suneja of "Guggenheim" Reiterated at Strong Buy and Held Target at $110 on, Thursday, June 15th, 2023

Contributing Sources